BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers (Basel) 2020;12:E186. [PMID: 31940916 DOI: 10.3390/cancers12010186] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu ZX, Yang Y, Zeng L, Patel H, Bo L, Lin L, Chen ZS. Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Front Oncol 2020;10:624954. [PMID: 33692943 DOI: 10.3389/fonc.2020.624954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhang Y, Wu ZX, Yang Y, Wang JQ, Li J, Sun Z, Teng QX, Ashby CR Jr, Yang DH. Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. Cancers (Basel) 2020;12:E3249. [PMID: 33158067 DOI: 10.3390/cancers12113249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
3 Wang JQ, Wu ZX, Yang Y, Li JS, Yang DH, Fan YF, Chen ZS. Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Front Oncol 2021;11:731260. [PMID: 34631561 DOI: 10.3389/fonc.2021.731260] [Reference Citation Analysis]
4 Wu ZX, Mai Q, Yang Y, Wang JQ, Ma H, Zeng L, Chen ZS, Pan Y. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomed Pharmacother 2021;136:111223. [PMID: 33450491 DOI: 10.1016/j.biopha.2021.111223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen XY, Yang Y, Wang JQ, Wu ZX, Li J, Chen ZS. Overexpression of ABCC1 Confers Drug Resistance to Betulin. Front Oncol 2021;11:640656. [PMID: 33718236 DOI: 10.3389/fonc.2021.640656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Patel H, Wu ZX, Chen Y, Bo L, Chen ZS. Drug resistance: from bacteria to cancer. Mol Biomed 2021;2:27. [PMID: 35006446 DOI: 10.1186/s43556-021-00041-4] [Reference Citation Analysis]
7 Wu ZX, Peng Z, Yang Y, Wang JQ, Teng QX, Lei ZN, Fu YG, Patel K, Liu L, Lin L, Zou C, Chen ZS. M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Front Oncol 2020;10:674. [PMID: 32477940 DOI: 10.3389/fonc.2020.00674] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lei ZN, Teng QX, Zhang W, Fan YF, Wang JQ, Cai CY, Lu KW, Yang DH, Wurpel JND, Chen ZS. Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. Front Cell Dev Biol 2020;8:607275. [PMID: 33425914 DOI: 10.3389/fcell.2020.607275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Moosavi F, Giovannetti E, Peters GJ, Firuzi O. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Crit Rev Oncol Hematol 2021;160:103234. [PMID: 33497758 DOI: 10.1016/j.critrevonc.2021.103234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wang JQ, Cui Q, Lei ZN, Teng QX, Ji N, Lin L, Liu Z, Chen ZS. Insights on the structure-function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. MedComm (2020) 2021;2:221-35. [PMID: 34766143 DOI: 10.1002/mco2.65] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wu ZX, Yang Y, Wang JQ, Zhou WM, Chen J, Fu YG, Patel K, Chen ZS, Zhang JY. Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. Front Pharmacol 2020;11:615824. [PMID: 33519482 DOI: 10.3389/fphar.2020.615824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Wu ZX, Yang Y, Wang G, Wang JQ, Teng QX, Sun L, Lei ZN, Lin L, Chen ZS, Zou C. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. Cancer Sci 2020;111:2872-82. [PMID: 32478948 DOI: 10.1111/cas.14505] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
13 Wang JQ, Teng QX, Lei ZN, Ji N, Cui Q, Fu H, Lin L, Yang DH, Fan YF, Chen ZS. Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Front Cell Dev Biol 2020;8:601400. [PMID: 33364237 DOI: 10.3389/fcell.2020.601400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Xu X, Yao L. Recent Patents on the Development of c-Met Kinase Inhibitors. PRA 2020;15:228-38. [DOI: 10.2174/1574892815666200630102344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wu ZX, Teng QX, Yang Y, Acharekar N, Wang JQ, He M, Yoganathan S, Lin J, Wang J, Chen ZS. MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study. Acta Pharm Sin B 2022;12:2609-18. [PMID: 35646541 DOI: 10.1016/j.apsb.2021.12.018] [Reference Citation Analysis]
16 Namasivayam V, Silbermann K, Pahnke J, Wiese M, Stefan SM. Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA). Comput Struct Biotechnol J 2021;19:3269-83. [PMID: 34141145 DOI: 10.1016/j.csbj.2021.05.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ding B, Bao C, Jin L, Xu L, Fan W, Lou W. CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death. Front Oncol 2021;11:681683. [PMID: 34249726 DOI: 10.3389/fonc.2021.681683] [Reference Citation Analysis]
18 Wang JQ, Yang Y, Cai CY, Teng QX, Cui Q, Lin J, Assaraf YG, Chen ZS. Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resist Updat 2021;54:100743. [PMID: 33513557 DOI: 10.1016/j.drup.2021.100743] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
19 Wang JQ, Wang B, Ma LY, Shi Z, Liu HM, Liu Z, Chen ZS. Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Exp Cell Res 2021;405:112728. [PMID: 34246653 DOI: 10.1016/j.yexcr.2021.112728] [Reference Citation Analysis]
20 Yang Y, Wu ZX, Wang JQ, Teng QX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS, Yang DH. OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Front Pharmacol 2021;12:620874. [PMID: 33658942 DOI: 10.3389/fphar.2021.620874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, Jani KA, Kaushal N, Chen ZS. ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evid Based Med 2021. [PMID: 34388310 DOI: 10.1111/jebm.12434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Wu ZX, Yang Y, Wang JQ, Narayanan S, Lei ZN, Teng QX, Zeng L, Chen ZS. Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Front Cell Dev Biol 2021;9:697927. [PMID: 34336849 DOI: 10.3389/fcell.2021.697927] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Fu H, Wu ZX, Lei ZN, Teng QX, Yang Y, Ashby CR, Lei Y, Lian Y, Chen ZS. The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Front Pharmacol 2022;13:861642. [PMID: 35350768 DOI: 10.3389/fphar.2022.861642] [Reference Citation Analysis]